Comparative Pharmacology
Head-to-head clinical analysis: GENTAK versus KANTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAK versus KANTREX.
GENTAK vs KANTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and causing mRNA misreading.
Gentamicin 3-5 mg/kg IV or IM once daily; alternatively, 1.5-2.5 mg/kg IV or IM every 8 hours.
15 mg/kg/day IM or IV divided every 8-12 hours (not to exceed 1.5 g/day)
None Documented
None Documented
2–3 hours in adults with normal renal function; prolonged to 24–60 hours in severe renal impairment (CrCl <10 mL/min).
2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; clinically significant accumulation in renal impairment requires monitoring
Renal excretion of unchanged drug accounts for >90% of elimination; <5% biliary/fecal.
Renal: 80-100% as unchanged drug via glomerular filtration; fecal: <1%
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic